Emerging data suggest Retatrutide , a dual stimulator targeting both the gut-brain axis and GIP , may provide a promising step forward for weight treatment. Initial clinical tests have shown impressive losses in visceral tissue, potentially outperforming other weight-loss treatments. Nevertheless , further evaluation is required to completely under